top

  Info

  • Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.

  Info

  • Utilizzare questo link per rimuovere la selezione effettuata.
Advances and Novel Treatment Options in Metastatic Melanoma
Advances and Novel Treatment Options in Metastatic Melanoma
Autore Facchiano Antonio
Pubbl/distr/stampa Basel, : MDPI - Multidisciplinary Digital Publishing Institute, 2022
Descrizione fisica 1 electronic resource (528 p.)
Soggetto topico Medicine
Soggetto non controllato melanoma
invasion
WNT5A
MARCKS
phosphorylation
MANS peptide
nanoparticles
cell therapy
tumor microenvironment
sex/gender
sex-hormones
immunity
microRNAs
immunotherapy
BRAF-mutant melanoma
BRAF inhibitor
mechanism of action
targeted therapy
tumour microenvironment
plasmacytoid dendritic cells
lactate dehydrogenase
TLR
interferon
CXCL10
TPC2
HIPPO
SOCE
metastasis
essential oils
angiogenesis
apoptosis
uveal melanoma (UM)
metastatic uveal melanoma (mUM)
prognostication
adjuvant therapy
metastatic therapy
metastatic dormancy
liver-directed-therapies
targeted-therapy
combined therapy
protein tyrosine phosphatase
PTPs inhibitors
melanoma immune infiltrate
BRAF inhibitors
microenvironment
resistance
therapy
therapeutic resistance
exosomes
extracellular vesicles
diagnosis
prognosis
ctDNA
liquid biopsy
prediction
patient stratification
BRAF
arthralgia
rheumatoid arthritis
carbonic anhydrase
hedgehog
cyclopamine
small molecules
acetazolamide
motility
metalloproteinases
FAK
cancer
mucosal melanoma
nivolumab
pembrolizumab
ipilimumab
radiotherapy
cholinergic system
acetylcholine
muscarinic receptors
nicotinic receptors
melanoma metastasis
ShcD adaptor protein
amoeboid motility
Rac1
DOCK4
melanoma PDX
target therapy
cancer stem cells
slow cycling phenotype
drug resistance
OXPHOS
lipid metabolism
cancer associated fibroblast
melanomagenesis
biomarkers
checkpoint inhibitor
PD-1
melanoma markers
cytokines
machine learning
Support Vector Machine
principal component analysis
BCL2L10
STAT3
cytotoxicity
survival
ABT-737
Bcl-2 family
ML258
HuR
MITF
metastases
siRNA
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Record Nr. UNINA-9910557612103321
Facchiano Antonio  
Basel, : MDPI - Multidisciplinary Digital Publishing Institute, 2022
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
New Prognostic and Predictive Markers in Cancer Progression
New Prognostic and Predictive Markers in Cancer Progression
Autore Costantini Susan
Pubbl/distr/stampa Basel, Switzerland, : MDPI - Multidisciplinary Digital Publishing Institute, 2021
Descrizione fisica 1 electronic resource (294 p.)
Soggetto topico Medicine
Soggetto non controllato MSI2
OSCC
oral cancer
musashi 2
prognosis
N-cadherin
EMT
breast cancer
new metastasis
eribulin
blood
biomarker
bladder cancer
immune checkpoint inhibitor
CD8+ T effector cells
microRNA
biomarkers
head and neck cancer
laryngeal cancer
prediction
metastasis
lifestyle habit
chemo-/radio resistance
therapeutic target
AKT
AR
castration-resistant prostate cancer (CRPC)
MAPK
mTOR
PI3K
prostate cancer
therapeutic resistance
WNT
miRNA
melanoma
melanoma resistance to MAPK/MEK inhibitors
resistance to immune checkpoint inhibitors
TNBC
BRCA1/2
HRR
PDL1
TILs
PI3KCA
PTEN
CTCs
CSC
pancreatic cancer
K-RAS oncogene
oncogene dependency
targeted therapies
genomic mutations
transcriptomics
metabolomics
selenoproteins
cancer
HUB nodes
major histocompatibility complex (MHC)
human leukocyte antigen (HLA)
antigen processing machinery (APM) molecules
carcinogenesis
tumor predisposition
cancer immunotherapy
pheochromocytoma
paraganglioma
head and neck neoplasms
head and neck tumors
genetic syndromes
mutations
hyperglycemia
cardioncology
nivolumab
cytokines
cardiotoxicity
acetyltransferase
cancer prognosis
NAA10
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Record Nr. UNINA-9910557794803321
Costantini Susan  
Basel, Switzerland, : MDPI - Multidisciplinary Digital Publishing Institute, 2021
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
Non-small Cell Lung Cancer: Current Therapies and New Targeted Treatments
Non-small Cell Lung Cancer: Current Therapies and New Targeted Treatments
Autore Uchino Junji
Pubbl/distr/stampa Basel, Switzerland, : MDPI - Multidisciplinary Digital Publishing Institute, 2021
Descrizione fisica 1 electronic resource (258 p.)
Soggetto topico Medicine
Soggetto non controllato non-small cell lung cancer
previously treated patients
phase I/II trial
chemotherapy
docetaxel
S-1
immunotherapy
rechallenge
retrospective analysis
pulmonary pleomorphic carcinoma
prognostic factor
glucose transporter 1
lung cancer
multiple cancers
metastasis
sequencing
mutation
genomic diagnosis
FDG-PET
immune checkpoint inhibitor
PD-1
prognosis
RAD51B methylation
PD-L1 expression
predictive biomarker
PD-1 blockade
interstitial lung disease
pulmonary fibrosis
radiology and other imaging
non-small-cell lung cancer
epidermal growth factor receptor
tyrosine kinase inhibitors
TP53 mutations
responsiveness
targeted therapy
network meta-analysis
stage IIIA-N2
surgery
immune checkpoint inhibitors
biomarker
nonsmall cell lung cancer
HIP1R
PD-L1
RUNX1
methylation
survival
EGFR-TKI
T790M
osimertinib
immune-related adverse events
endocrine disorders
tumor-bearing patients
PD-1 inhibitors
PD-L1 inhibitors
meta-analysis
nivolumab
Expanded Access Program
real-world data
daily practice
prognostic factors
NSCLC
KRAS
DNA polymerase beta
platinum-based first-line
adjuvant chemotherapy
β-catenin
lung neoplasms
nucleotide-diphosphate kinase
recurrence
unresectable
salvage surgery
oligometastasis
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Altri titoli varianti Non-small Cell Lung Cancer
Record Nr. UNINA-9910557489703321
Uchino Junji  
Basel, Switzerland, : MDPI - Multidisciplinary Digital Publishing Institute, 2021
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
Present and Future of Personalised Medicine for Endocrine Cancers
Present and Future of Personalised Medicine for Endocrine Cancers
Autore Ronchi Cristina L
Pubbl/distr/stampa Basel, : MDPI - Multidisciplinary Digital Publishing Institute, 2022
Descrizione fisica 1 electronic resource (140 p.)
Soggetto topico Medicine
Soggetto non controllato papillary thyroid cancer
SUV PET/CT
BRAF V600E
immune checkpoint inhibitors (ICIs)
ipilimumab
nivolumab
prolactinoma
Cushing's disease
aggressive pituitary tumor
aggressive PitNET
aggressive pituitary adenoma
pituitary carcinoma
adrenocortical cancer
adrenal adenomas
adrenal tumors
p53
p27
ki-67
reticulin
mitotane
adjuvant treatment
recurrence
recurrence free survival
timing
intratumoral heterogeneity
thyroid tumor
BRAF
RET/PTC rearrangements
RAS mutation
adrenal cortex
carcinoma
angiogenesis
gene expression
osteopontin
hyaluronan synthase 1
multikinase inhibitors
sorafenib
lenvatinib
differentiated thyroid cancer
radioiodine resistance
predictive marker
predictors
response to treatment
survival
information needs and preferences
focus group interview
personalized medicine
neuroendocrine tumours
phaeochromocytoma
paraganglioma
molecular clusters
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Record Nr. UNINA-9910576879703321
Ronchi Cristina L  
Basel, : MDPI - Multidisciplinary Digital Publishing Institute, 2022
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
Small Cell Lung Cancer: A New Era Is Beginning?
Small Cell Lung Cancer: A New Era Is Beginning?
Autore Morabito Alessandro
Pubbl/distr/stampa Basel, Switzerland, : MDPI - Multidisciplinary Digital Publishing Institute, 2021
Descrizione fisica 1 electronic resource (150 p.)
Soggetto topico Medicine
Soggetto non controllato immune checkpoint inhibitors
extensive-stage small cell lung cancer
nivolumab
ipilimumab
pembrolizumab
atezolizumab
durvalumab
chemotherapy
small-cell lung cancer
lobectomy
pneumonectomy
radiotherapy
multimodal treatment
immunotherapy
SCLC
PARP
DDR
ICB
synthetic lethality
SLFN11
STING
pathology and classification of SCLC
biology of SCLC
immune-checkpoint inhibitors in SCLC
small cell lung cancer
Immunotherapy
extensive disease
lurbinectedin
gene pathway
pathobiology
targeted therapy
circulating tumor cells
prognostic biomarker
targeted agents
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Altri titoli varianti Small Cell Lung Cancer
Record Nr. UNINA-9910557380603321
Morabito Alessandro  
Basel, Switzerland, : MDPI - Multidisciplinary Digital Publishing Institute, 2021
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui